MLP Care (MPARK) 3Q26 Financial Results
Tacirler Investment
We view the company's 3Q26 financial results as slightly positive, driven by revenues broadly in line with market expectations, stronger-than-expected EBITDA and improving operational margins. We believe new hospital investments and strong cash generation support the company's medium-term growth outlook. MLP Saglik remains in our model portfolio with a 12-month target price of TL645 per share and a BUY recommendation.






